SCHEMBL2818375

SCHEMBL2818375

CCOC(=O)C[C@H](O[SiH2]C(C)(C)C(C)C)c1ccc2oc(C)nc2c1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 8/20 0.39
TAS1R1 Q7RTX1 8/20 0.39
THRB P10828 2/20 0.37
TP53 P04637 1/20 0.37
ACACB O00763 1/20 0.36
RAB9A P51151 3/20 0.34
NPC1 O15118 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
STAT1 P42224 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
LMNA P02545 1/20 0.34
OGA O60502 1/20 0.34
MAOA P21397 1/20 0.34
ADRA1A P35348 1/20 0.34
MAPT P10636 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
POLB P06746 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2820766 0.83 TAS1R3 (0.36) TAS1R3TAS1R1TP53ACACBRAB9A
SCHEMBL2824960 0.82 L3MBTL1 (0.36) TAS1R3TAS1R1TP53ACACBRAB9A
SCHEMBL2818376 0.82 TAS1R3 (0.39) TAS1R3TAS1R1THRBTP53ACACB
SCHEMBL12600115 0.78 TAS1R3 (0.44) TAS1R3TAS1R1THRBTP53ACACB
SCHEMBL2819074 0.67 GAA (0.37) TAS1R3TAS1R1TP53ACACBRAB9A
SCHEMBL12600066 0.66 TAS1R3 (0.54) TAS1R3TAS1R1RAB9ANPC1SMN1; SMN2
SCHEMBL17385279 0.66 CYP4F2 (0.51) TAS1R3TAS1R1RAB9ANPC1SMN1; SMN2
SCHEMBL2821994 0.66 L3MBTL1 (0.38) TAS1R3TAS1R1TP53ACACBRAB9A
SCHEMBL10315088 0.65 GAA (0.47) TAS1R3TAS1R1TP53RAB9ANPC1
SCHEMBL12600153 0.65 SMN1; SMN2 (0.38) TAS1R3TAS1R1RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7700621-B2 E.g., 4-(2-methyl-3-oxo-hept-6-en-2-yl)-2,2-dimethyl-[1,3]-dioxane chemical intermediate; chemical/metabolic stabilization of microtubuli; antitumor, -carcinogenic agents; malignant melanoma, acute lymphocytic/myelocytic leukemia; angiogenesis inhibitors; antiinflammatory/-arthritic agents; psoriasis BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-04-20 US disclosed
US-20060046997-A1 6-Alkenyl -, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations BAYER INTELLECTUAL PROPERTY GMBH (DE) 2006-03-02 US disclosed
EP-1173441-A1 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTHILONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE IN PHARMACEUTICAL PREPARATIONS SCHERING AKTIENGESELLSCHAFT (DE) 2002-01-23 EP disclosed
WO-2000066589-A1 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTHILONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE IN PHARMACEUTICAL PREPARATIONS SCHERING AKTIENGESELLSCHAFT (DE) 2000-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060046997-A1 6-Alkenyl -, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations TUBB6, CCNB1, TUBB TAS1R3 3550/4885TAS1R1 3147/4885THRB 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.